Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Assessing the Efficacy, Safety, and Pharmacokinetics of 75 and 100 mg Once-a-month Delayed-release Risedronate Formulations Compared to 150 mg Once-a-month Immediate-release Risedronate for 3 Months in Postmenopausal Women Age 45-80

NCT00918749 is registered in ClinicalTrials.gov with Warner Chilcott as lead sponsor.

NCT NCT00918749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00918749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Assessing the Efficacy, Safety, and Pharmacokinetics of 75 and 100 mg Once-a-month Delayed-release Risedronate Formulations Compared to 150 mg Once-a-month Immediate-release Risedronate for 3 Months in Postmenopausal Women Age 45-80
Lead sponsor
Warner Chilcott
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
October 31, 2009
Enrollment
205 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis